Frequency and percentage of self-reported medical late effects comparing transplant types
. | . | Type of transplant . | . | . | ||
---|---|---|---|---|---|---|
. | Total, no. (%) . | Autologous, no. (%) . | Related donor, no. % . | Unrelated donor, no. (%) . | ||
No. | 248 (100.0) | 28 (100.0) | 150 (100.0) | 70 (100.0) | ||
Eye impairments* | 121 (48.8) | 8 (28.6) | 73 (48.7) | 40 (57.1) | ||
Cataracts | 95 (38.3) | 6 (21.4) | 57 (38.0) | 32 (45.7) | ||
Glaucoma | 4 (1.6) | 0 (0.0) | 2 (1.3) | 2 (2.8) | ||
Very dry eyes | 62 (25.0) | 3 (10.7) | 36 (24.0) | 23 (32.9) | ||
Oral health impairments | 66 (26.6) | 5 (17.9) | 41 (27.3) | 20 (28.6) | ||
Dry mouth | 34 (13.7) | 2 (7.1) | 21 (14.0) | 11 (15.7) | ||
Swollen or bleeding gums | 28 (11.3) | 2 (7.1) | 18 (12.0) | 8 (11.4) | ||
Problems chewing or swallowing | 24 (9.7) | 2 (7.1) | 15 (10.0) | 7 (10.0) | ||
Endocrine impairments | 63 (25.4) | 9 (32.1) | 38 (25.3) | 16 (22.9) | ||
Hyperthyroid | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0 (0.0) | ||
Hypothyroid | 37 (14.9) | 5 (17.9) | 22 (14.7) | 10 (14.3) | ||
Thyroid nodules | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Diabetes | 30 (12.1) | 5 (17.9) | 18 (12.0) | 7 (10.0) | ||
Bone and joint health | 31 (12.5) | 2 (7.1) | 18 (12.0) | 11 (15.7) | ||
Osteoporosis | 24 (9.7) | 2 (7.1) | 14 (9.3) | 8 (11.4) | ||
Avascular necrosis | 9 (3.6) | 0 (0.0) | 5 (3.3) | 4 (5.7) | ||
Cardiopulmonary impairments† | 81 (32.7) | 5 (17.9) | 44 (29.3) | 32 (45.7) | ||
Arrhythmias | 17 (6.8) | 0 (0.0) | 8 (5.3) | 9 (12.9) | ||
Congestive heart failure | 2 (0.8) | 1 (3.6) | 0 (0.0) | 1 (1.4) | ||
Myocardial infarction | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Coronary heart disease | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0 (0.0) | ||
Hypertension | 51 (20.6) | 3 (10.7) | 30 (20.0) | 18 (25.7) | ||
Stroke | 3 (1.2) | 0 (0.0) | 2 (1.3) | 1 (1.4) | ||
Angina | 3 (1.2) | 0 (0.0) | 3 (2.0) | 0 (0.0) | ||
Exercise-induced shortness of breath‡ | 23 (9.3) | 1 (3.6) | 10 (6.7) | 12 (17.1) | ||
Pericarditis | 4 (1.6) | 0 (0.0) | 3 (2.0) | 1 (1.4) | ||
Stiff or leaking heart valves | 2 (0.8) | 0 (0.0) | 1 (0.7) | 1 (1.4) | ||
Blood clots | 10 (4.0) | 2 (7.1) | 3 (2.0) | 5 (7.1) | ||
Lung fibrosis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Gastrointestinal impairments | 43 (17.3) | 3 (10.7) | 29 (19.3) | 11 (15.7) | ||
Gallstones | 24 (9.7) | 2 (7.1) | 14 (9.3) | 8 (11.4) | ||
Cirrhosis | 5 (2.0) | 0 (0.0) | 3 (2.0) | 2 (2.9) | ||
Hepatitis | 15 (6.0) | 1 (3.6) | 12 (8.0) | 2 (2.9) | ||
Disease of esophagus | 8 (3.2) | 0 (0.0) | 5 (3.3) | 3 (4.3) | ||
Neurosensory impairments | 100 (40.3) | 11 (39.3) | 56 (37.3) | 33 (47.1) | ||
Blindness | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0 (0.0) | ||
Complete or partial deafness | 8 (3.2) | 1 (3.6) | 5 (3.3) | 2 (2.9) | ||
Tinnitus | 20 (8.1) | 2 (7.1) | 15 (10.0) | 3 (4.3) | ||
Dizziness or vertigo | 16 (6.4) | 2 (7.1) | 10 (6.7) | 4 (5.7) | ||
Loss of, or abnormal sense of, taste/smell§ | 46 (18.5) | 1 (3.6) | 27 (18.0) | 18 (25.7) | ||
Loss of, or abnormal sense of, touch | 53 (21.4) | 7 (25.0) | 27 (18.0) | 19 (27.1) | ||
Neuromotor impairments | 51 (20.6) | 3 (10.7) | 28 (18.7) | 20 (28.6) | ||
Paralysis | 3 (1.2) | 0 (0.0) | 2 (1.3) | 1 (1.4) | ||
Balance, tremor, or weakness | 50 (20.2) | 3 (10.7) | 27 (18.0) | 20 (28.6) | ||
Chronic GVHD¶ | 95 (38.3) | 0 (0.0) | 54 (36.0) | 41 (58.6) | ||
Skin | 26 (10.5) | 0 (0.0) | 16 (10.7) | 10 (14.3) | ||
Liver | 11 (4.4) | 0 (0.0) | 7 (4.7) | 4 (5.7) | ||
Gastrointestinal | 12 (4.8) | 0 (0.0) | 7 (4.7) | 5 (7.1) | ||
Lungs | 3 (1.2) | 0 (0.0) | 1 (0.7) | 2 (2.9) | ||
Eyes | 7 (2.8) | 0 (0.0) | 5 (3.3) | 2 (2.9) | ||
Joints | 11 (4.4) | 0 (0.0) | 8 (5.3) | 3 (4.3) | ||
Second or third malignancies | ||||||
Second cancer | 21 (8.5) | 3 (10.7) | 10 (6.7) | 8 (11.4) | ||
Third malignancy | 4 (1.6) | 0 (0.0) | 3 (2.0) | 1 (1.4) |
. | . | Type of transplant . | . | . | ||
---|---|---|---|---|---|---|
. | Total, no. (%) . | Autologous, no. (%) . | Related donor, no. % . | Unrelated donor, no. (%) . | ||
No. | 248 (100.0) | 28 (100.0) | 150 (100.0) | 70 (100.0) | ||
Eye impairments* | 121 (48.8) | 8 (28.6) | 73 (48.7) | 40 (57.1) | ||
Cataracts | 95 (38.3) | 6 (21.4) | 57 (38.0) | 32 (45.7) | ||
Glaucoma | 4 (1.6) | 0 (0.0) | 2 (1.3) | 2 (2.8) | ||
Very dry eyes | 62 (25.0) | 3 (10.7) | 36 (24.0) | 23 (32.9) | ||
Oral health impairments | 66 (26.6) | 5 (17.9) | 41 (27.3) | 20 (28.6) | ||
Dry mouth | 34 (13.7) | 2 (7.1) | 21 (14.0) | 11 (15.7) | ||
Swollen or bleeding gums | 28 (11.3) | 2 (7.1) | 18 (12.0) | 8 (11.4) | ||
Problems chewing or swallowing | 24 (9.7) | 2 (7.1) | 15 (10.0) | 7 (10.0) | ||
Endocrine impairments | 63 (25.4) | 9 (32.1) | 38 (25.3) | 16 (22.9) | ||
Hyperthyroid | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0 (0.0) | ||
Hypothyroid | 37 (14.9) | 5 (17.9) | 22 (14.7) | 10 (14.3) | ||
Thyroid nodules | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Diabetes | 30 (12.1) | 5 (17.9) | 18 (12.0) | 7 (10.0) | ||
Bone and joint health | 31 (12.5) | 2 (7.1) | 18 (12.0) | 11 (15.7) | ||
Osteoporosis | 24 (9.7) | 2 (7.1) | 14 (9.3) | 8 (11.4) | ||
Avascular necrosis | 9 (3.6) | 0 (0.0) | 5 (3.3) | 4 (5.7) | ||
Cardiopulmonary impairments† | 81 (32.7) | 5 (17.9) | 44 (29.3) | 32 (45.7) | ||
Arrhythmias | 17 (6.8) | 0 (0.0) | 8 (5.3) | 9 (12.9) | ||
Congestive heart failure | 2 (0.8) | 1 (3.6) | 0 (0.0) | 1 (1.4) | ||
Myocardial infarction | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Coronary heart disease | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0 (0.0) | ||
Hypertension | 51 (20.6) | 3 (10.7) | 30 (20.0) | 18 (25.7) | ||
Stroke | 3 (1.2) | 0 (0.0) | 2 (1.3) | 1 (1.4) | ||
Angina | 3 (1.2) | 0 (0.0) | 3 (2.0) | 0 (0.0) | ||
Exercise-induced shortness of breath‡ | 23 (9.3) | 1 (3.6) | 10 (6.7) | 12 (17.1) | ||
Pericarditis | 4 (1.6) | 0 (0.0) | 3 (2.0) | 1 (1.4) | ||
Stiff or leaking heart valves | 2 (0.8) | 0 (0.0) | 1 (0.7) | 1 (1.4) | ||
Blood clots | 10 (4.0) | 2 (7.1) | 3 (2.0) | 5 (7.1) | ||
Lung fibrosis | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Gastrointestinal impairments | 43 (17.3) | 3 (10.7) | 29 (19.3) | 11 (15.7) | ||
Gallstones | 24 (9.7) | 2 (7.1) | 14 (9.3) | 8 (11.4) | ||
Cirrhosis | 5 (2.0) | 0 (0.0) | 3 (2.0) | 2 (2.9) | ||
Hepatitis | 15 (6.0) | 1 (3.6) | 12 (8.0) | 2 (2.9) | ||
Disease of esophagus | 8 (3.2) | 0 (0.0) | 5 (3.3) | 3 (4.3) | ||
Neurosensory impairments | 100 (40.3) | 11 (39.3) | 56 (37.3) | 33 (47.1) | ||
Blindness | 1 (0.4) | 0 (0.0) | 1 (0.7) | 0 (0.0) | ||
Complete or partial deafness | 8 (3.2) | 1 (3.6) | 5 (3.3) | 2 (2.9) | ||
Tinnitus | 20 (8.1) | 2 (7.1) | 15 (10.0) | 3 (4.3) | ||
Dizziness or vertigo | 16 (6.4) | 2 (7.1) | 10 (6.7) | 4 (5.7) | ||
Loss of, or abnormal sense of, taste/smell§ | 46 (18.5) | 1 (3.6) | 27 (18.0) | 18 (25.7) | ||
Loss of, or abnormal sense of, touch | 53 (21.4) | 7 (25.0) | 27 (18.0) | 19 (27.1) | ||
Neuromotor impairments | 51 (20.6) | 3 (10.7) | 28 (18.7) | 20 (28.6) | ||
Paralysis | 3 (1.2) | 0 (0.0) | 2 (1.3) | 1 (1.4) | ||
Balance, tremor, or weakness | 50 (20.2) | 3 (10.7) | 27 (18.0) | 20 (28.6) | ||
Chronic GVHD¶ | 95 (38.3) | 0 (0.0) | 54 (36.0) | 41 (58.6) | ||
Skin | 26 (10.5) | 0 (0.0) | 16 (10.7) | 10 (14.3) | ||
Liver | 11 (4.4) | 0 (0.0) | 7 (4.7) | 4 (5.7) | ||
Gastrointestinal | 12 (4.8) | 0 (0.0) | 7 (4.7) | 5 (7.1) | ||
Lungs | 3 (1.2) | 0 (0.0) | 1 (0.7) | 2 (2.9) | ||
Eyes | 7 (2.8) | 0 (0.0) | 5 (3.3) | 2 (2.9) | ||
Joints | 11 (4.4) | 0 (0.0) | 8 (5.3) | 3 (4.3) | ||
Second or third malignancies | ||||||
Second cancer | 21 (8.5) | 3 (10.7) | 10 (6.7) | 8 (11.4) | ||
Third malignancy | 4 (1.6) | 0 (0.0) | 3 (2.0) | 1 (1.4) |
Eye impairments: frequency in related and unrelated donor groups greater than in autologous (P < .05).
Cardiopulmonary impairments: frequency in unrelated donor group greater than in both autologous and related donor groups (P < .05).
Exercise-induced shortness of breath: frequency in unrelated donor group greater than in both autologous and related donor groups (P < .05).
Loss of/abnormal sense of taste/smell: frequency in unrelated donor group greater than in autologous group (P < .05).
Chronic GVHD: frequency in unrelated donor group greater than in related donor group (P < .05).